Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2
Puig Sanz, Lluís ![Identificador ORCID](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Wu, Jashin ![Identificador ORCID](/img/uab/orcid.ico)
(Dermatology Research and Education Foundation)
Gooderham, Melinda ![Identificador ORCID](/img/uab/orcid.ico)
(SKiN Centre for Dermatology and Department of Medicine. Queen's University)
You, Yin (Biostatistics. Immunology. Janssen Research & Development. LLC)
Shen, Yaung-Kaung (Biostatistics. Immunology. Janssen Research & Development. LLC)
Randazzo, Bruce (Clinical Research. Janssen Research & Development. LLC)
Kerdel, Francisco
(Florida Academic Dermatology Centers)
Data: |
2021 |
Resum: |
Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Patients who self-identified as Hispanic (n = 117) or non-Hispanic (n = 1686) were randomized to guselkumab, placebo, or adalimumab. Efficacy assessments included Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Results: At week 16, treatment differences for guselkumab versus placebo in the Hispanic and non-Hispanic populations were 67. 4 (95% confidence interval 50. 4, 84. 4) and 77. 2 (73. 5, 80. 8) percentage points for IGA 0/1 and 59. 2 (41. 9, 76. 4) and 69. 2 (65. 7, 72. 7) percentage points for PASI 90, respectively. Treatment differences for guselkumab versus adalimumab were 25. 9 (6. 5, 45. 3) and 17. 5 (12. 8, 22. 3) percentage points for IGA 0/1 and 21. 4 (-0. 1, 42. 9) and 23. 5 (18. 2, 28. 9) percentage points for PASI 90, respectively. Week 24 results were similar. Adverse event frequency was greater in adalimumab- versus guselkumab-treated patients in the Hispanic population only through weeks 16 and 28. In both populations, DLQI 0/1 responses were greater in guselkumab-treated versus placebo- and adalimumab-treated patients at week 16 and versus adalimumab-treated patients at week 24. Conclusions: Guselkumab safety and efficacy were consistent between Hispanic and non-Hispanic populations. |
Nota: |
Altres ajuts: Janssen Research and Development (JRD) |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ![Creative Commons](/img/licenses/by-nc-nd.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Matèria: |
Guselkumab ;
Psoriasis ;
Hispanic |
Publicat a: |
Journal of Dermatological Treatment, Vol. 32 Núm. 5 (2021) , p. 484-491, ISSN 1471-1753 |
DOI: 10.1080/09546634.2019.1679336
PMID: 31613178
El registre apareix a les col·leccions:
Documents de recerca >
Documents dels grups de recerca de la UAB >
Centres i grups de recerca (producció científica) >
Ciències de la salut i biociències >
Institut de Recerca Sant PauArticles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2022-12-16, darrera modificació el 2023-11-30